Johnson & Johnson announced new pivotal Phase 3 clinical data for CAPLYTA (lumateperone) in treating bipolar mania, alongside additional findings in bipolar depression and major depressive disorder. The data, presented at the 2026 Psych Congress, highlight CAPLYTA's potential across mood disorders. The company also shared new analyses on SPRAVATO (esketamine) nasal spray for depression symptoms like anhedonia, and real-world evidence on long-acting injectables for schizophrenia and seltorexant for depression with insomnia. These updates underscore J&J's commitment to advancing treatments for complex neuropsychiatric conditions where patients face significant challenges.
The JPMorgan Equity Premium Income ETF (JEPI) delivers attractive monthly income by selling call options, which caps its upside potential. In contrast, three Dividend Kings—Coca-Cola, Johnson & Johnson, and Procter & Gamble—offer lower initial yields...
In 2026, among defensive stocks, Johnson & Johnson outperformed with a 35% gain driven by strong oncology and immunology sales and a robust pipeline. Coca-Cola followed with a 28% rise, benefiting from steady global volume and pricing power, while Pr...
Johnson & Johnson has increased its dividend for the 64th consecutive year, paying $1.34 per share quarterly, reflecting a 3.1% raise. The company maintains a strong financial position with a payout ratio near 48%, supported by robust operating cash ...
